Verification register Bio, Health & Neuro
Current reading
The readiness gap, in one scan
AI-assisted assembly · derived results
- Claimed
- 90
- Reported
- 89
- Verified
- 83
- Gap
- +7
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed minus verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-06-28
Adopt with guardrails
- Why
- Practice-changing Phase 3 data (first positive Phase 3 of a bispecific in myeloma) and full FDA approval put this at high maturity — but the infection/fatal-AE profile mandates real guardrails, and it is an approved drug rather than a speculative platform tech.
- Next
- Use as a reference exemplar of a mature, FDA-approved bispecific combination; apply infection-prophylaxis guardrails (IVIG + antimicrobial prophylaxis) per the MajesTEC-3 protocol amendment that reduced infection incidence.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 6
- Tier 1
- 0
- Tier 2
- 2
- Tier 3
- 4
- Supports
- 3
- Contradicts
- 1
- Context
- 2
- Latest observed
- 2026-03-05
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
This is the initial public reading. No earlier readiness change is recorded.